Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation

Meijun Long, Juekun Wu, Junwen Hao, Wei Liu, Yong Tang, Xi Li, Hang Su, Wanshou Qiu

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited effective treatment options. New therapeutic approaches are urgently needed to improve the prognosis of TNBC. Here we demonstrated that a redox modulator, selenocystine (SeC), significantly inhibits TNBC cell proliferation in a dose- and time-dependent manner. Through cell apoptosis assays and cell cycle distribution analyses, we have shown that the in vitro inhibitory effect of SeC on TNBC cells can be attributed to the induction of apoptosis and the S-phase arrest in a dose-dependent manner. Therefore, this finding implies that SeC potentially is a novel therapeutic agent for TNBC.

Original languageEnglish (US)
Pages (from-to)1077-1084
Number of pages8
JournalIn Vitro Cellular and Developmental Biology - Animal
Volume51
Issue number10
DOIs
StatePublished - Jul 21 2015

Keywords

  • Apoptosis
  • Proliferation
  • S-phase arrest
  • Selenocystine
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation'. Together they form a unique fingerprint.

  • Cite this